FAG
BIOC

Fortitude Advisory Group’s Biocept, Inc. BIOC Stock Holding History

Fortitude Advisory Group’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,067
Closed -$116K – 1617
2021
Q4 		$116K Buy
+1,067
New +$123K 0.06% 318

Other funds holding BIOC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fortitude Advisory Group's BIOC Position: Q1 2022 in Review

Fortitude Advisory Group sold out of Biocept, Inc. (BIOC) in Q1 2022, closing a stake of 1,067 shares — an estimated $116K sold.

Fortitude Advisory Group first reported a position in BIOC in Q4 2021 and held it in 1 quarter. The position peaked at $116K in Q4 2021. 27 funds tracked by Wall St. Rank hold BIOC as of Q1 2022.

  • Fortitude Advisory Group reported no remaining Biocept, Inc. position as of Q1 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 1,067 Biocept, Inc. shares in Q1 2022, an estimated $116K.
  • Fortitude Advisory Group first reported a position in Biocept, Inc. in Q4 2021 and held it in 1 quarter.
  • Fortitude Advisory Group's Biocept, Inc. position peaked at $116K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Biocept, Inc. as of Q1 2022.

Based on Fortitude Advisory Group's 13F filing for Q1 2022, filed 25 May 2022.